Advertisement
Daniel G. Welch has served as Chief Executive Officer and President ofInterMune since September 2003. Prior to InterMune, Mr. Welch was Chairmanand CEO of Triangle Pharmaceuticals, a biopharmaceutical company, which wasacquired by Gilead. From 2000 to 2002, he was President of Biopharmaceuticalsat Elan Corporation where he was responsible for U.S. commercial operations,the international subsidiaries, the R&D function and the diagnosticsbusinesses. Mr. Welch served in several senior management roles atSanofi-Aventis during the years 1987 to 2000, including Vice President ofWorldwide Marketing and COO of the U.S. business. Prior to joiningSanofi-Aventis, Mr. Welch was with American Critical Care, a division ofAmerican Hospital Supply. Mr. Welch is a member of the Board of Directors ofSeattle Genetics, Inc. and BayBio, the bay-area biotech industry association.He holds an M.B.A. from the University of North Carolina and a B.B.A. from theUniversity of Miami.
Advertisement
Dr. Gardner and Mr. Welch join current Corium board members John Kozarich,Chairman and President, ActivX Biosciences, Inc., Ron Eastman, Chairman of theBoard and Partner at Essex Woodlands Health Ventures, Robert Thomas, CEO ofCorium and former FoxHollow Technologies CEO, Gary Cleary, co-founder ofCorium and CTO, and Ravi Srinivasan, co-founder of Stratagent Life Sciencesand VP of Engineering at Corium. The Company recently completed a$25.1 million Series C financing led by Essex Woodlands Health Ventures.Corium is using the proceeds to continue the development and commercializationof a pipeline of advanced transdermal products employing its proprietaryMicroCor(TM) microneedle technology, Corplex(TM) polymer adhesive technology,and MicroJet liquid drug delivery technology.
Corium is headquartered in Menlo Park, CA, with manufacturing facilitiesin Grand Rapids, MI.
About Corium International, Inc.
Corium International, Inc. is a privately-owned company engaged in theresearch, development and manufacture of advanced transdermal drug deliverytechnologies and products. Using its proprietary delivery technologies and itsdevelopment and manufacturing expertise, Corium has developed a number ofactive and passive transdermal products with enhanced therapeutic or safetyprofiles. This self-funded product pipeline spans several therapeutic areasand is in various stages of development. Corium also has severalpartner-funded products with small, medium and large pharmaceutical companiesin various stages of development, ranging from manufacturing to research anddevelopment. Please visit http://www.coriumgroup.com
About Essex Woodlands Health Ventures
With $1.6 billion under management, Essex Woodlands is
